Forecast
The analysts' average price target is €7.59 (+0.93%). The median is €7.29 (-3.06%).
| Buy |
Â
6 |
| Hold |
Â
0 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
DiaMedica Q2 loss in line with guidance; clinical programs make progress
DiaMedica reported an adjusted loss of $0.19 per share in the second quarter, exactly matching consensus, and no revenue. The biotech company observed significant blood pressure effects in the late preeclampsia study, completed the first cohort in the early fetal growth restriction trial, and has recruited over 85% of patients for the ReMEDy2 stroke interim analysis. Cash and equivalents amounted to $43.5 million as of June 30, which management says should fund operations and studies through 2027, while R&D expenses rose markedly. The stock reacted positively in premarket trading; near‑term milestones include further cohort recruitment, top‑line data and steps toward a U.S. IND submission. » More on de.investing.com
1 Main Capital highlights DiaMedica Therapeutics for DM199 stroke‑recovery potential
1 Main Capital said it holds an opportunistic position in DiaMedica Therapeutics, citing DM199, a recombinant form of tissue kallikrein‑1 (KLK1), as a promising therapy for ischemic stroke recovery. The fund noted extensive real‑world use of naturally derived KLK1 in China and positive signals from pooled and Phase 4 studies, while acknowledging those data are not FDA‑caliber and DM199 is not identical to the Chinese product. DiaMedica closed at $6.34 on July 31, 2026, with a market cap near $342 million and mixed recent returns. » More on finance.yahoo.com
DiaMedica Therapeutics strengthens liquidity and reports slightly better EPS for Q4 2025
DiaMedica Therapeutics reported Q4 2025 EPS of -$0.17, slightly above expectations, and increased cash and equivalents to $59.9 million (+35.8%). Operating cash outflow rose due to higher R&D spending, including the expansion of the ReMEDy2 study. Management expects current liquidity to fund operations through the end of 2027; the stock fell 2.21% in after-hours trading. » More on de.investing.com
DiaMedica receives Health Canada approval for phase-2 study of DM199 in early-onset preeclampsia
DiaMedica has received a 'No Objection Letter' from Health Canada to start an open-label phase-2 dose-finding study of DM199 in early-onset preeclampsia. The study, planned for 2026, will test three dose levels, administer DM199 subcutaneously every three days until delivery, and assess safety, tolerability and exploratory efficacy markers such as pulsatility index, sFlt‑1 and placental growth factor. The company plans to expand the study to the US and the UK after regulatory clearances. According to the data, DiaMedica shows high short-term liquidity; analysts have price targets between $11 and $25, while InvestingPro currently considers the stock overvalued. » More on de.investing.com
DiaMedica must conduct additional non-clinical study for DM199 after FDA talks
The FDA requires, before an IND filing for treatment of early-onset preeclampsia, a 10-day modified embryo‑fetal plus pre- and postnatal study in rabbits, with results expected by Q2 2026. DiaMedica announced it will carry out this study for its drug DM199 (Rinvecalinas‑Alfa) and said the talks provided regulatory clarity on the non-clinical data package. At the same time, an investigator-initiated phase‑2 trial in South Africa is already treating more than 30 women with late-stage preeclampsia; preliminary data show encouraging safety and efficacy signals. Analysts have lowered their earnings estimates following the news, and the stock has recently fallen. » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsIn 2022, DIAMEDICA THERAPEUT. has already paid €2.74 in dividends. The last payout was in March 2022.
Financials
In the last quarter, DIAMEDICA THERAPEUT. had revenue of €0 and net profit of -€9.99M
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | - |
| Net profit | -9.99M | 35.94% |
| EBITDA | -9.97M | 36.08% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €405.69M |
Number of shares | 53.96M |
52-week high/low | €10.02 - €4.78 |
| Dividends | No |
Beta | 0.94 |
P/E ratio | -10.86 |
PEG ratio | 1.57 |
P/B ratio | 15.53 |
P/S ratio | 0.00 |
Company profile
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
| Name | DIAMEDICA THERAPEUT. |
| CEO | Dietrich John Pauls |
| Headquarters | Minneapolis,
mn USA |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 08/03/2012 |
| Employees | 35 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | DMAC |